Norwalk Leslie V 4
4 · NEUROCRINE BIOSCIENCES INC · Filed Jun 8, 2026
Research Summary
AI-generated summary of this filing
Neurocrine (NBIX) Director Leslie Norwalk Sells 1,250 Shares
What Happened Leslie V. Norwalk, a director of Neurocrine Biosciences (NBIX), sold 1,250 shares on June 4, 2026, for total proceeds of approximately $210,072. The weighted-average sale price was $168.06 per share; individual trades occurred at prices between $168.00 and $168.2550. This was a sale (not a purchase or option exercise).
Key Details
- Transaction date: June 4, 2026 (reported on Form 4 filed June 8, 2026).
- Type: Open-market sale (code S).
- Shares sold: 1,250; weighted average price: $168.06; total proceeds ≈ $210,072.
- Sale executed by a broker pursuant to a Rule 10b5-1 trading plan adopted Sept 15, 2025; issuer policy prevents amending the plan after adoption (Footnote F1).
- Shares were sold in multiple trades at $168.00–$168.2550; issuer/filing will provide breakdown on request (Footnote F2).
- Shares owned after transaction: not specified in the provided filing.
Context The sale was effected under a pre-established 10b5-1 plan, which is commonly used to automate insider sales and reduce concerns about trading on non-public information. The Form 4 was filed within the standard two-business-day window and does not, by itself, indicate the insider’s view of the company.
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-06-04$168.06/sh−1,250$210,072→ 2,838 total
Footnotes (2)
- [F1]The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted and effective on September 15, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- [F2]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $168.00 to $168.2550. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.